We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DGX icon
151
Quest Diagnostics
DGX
$25.1B
$1.89M 0.02%
+13,000
New +$1.9M
XNCR icon
152
Xencor
XNCR
$1.44B
$1.7M 0.02%
52,100
-1,000
-2% -$32.8K
ARCT icon
153
Arcturus Therapeutics
ARCT
$157M
$1.65M 0.02%
+34,500
New +$1.55M
APLS
154
DELISTED
Apellis Pharmaceuticals
APLS
$1.58M 0.02%
48,000
– –
ZTS icon
155
Zoetis
ZTS
$31.6B
$1.38M 0.01%
7,100
– –
KURA icon
156
Kura Oncology
KURA
$922M
$1.08M 0.01%
57,500
-500
-0.9% -$9.42K
CLLS
157
Cellectis
CLLS
$286M
$1.04M 0.01%
82,500
-1,000
-1% -$13.9K
ACIU icon
158
AC Immune
ACIU
$227M
$933K 0.01%
+139,000
New +$995K
KOS icon
159
Kosmos Energy
KOS
$1.56B
$864K 0.01%
292,000
– –
FTNT icon
160
Fortinet
FTNT
$112B
$642K 0.01%
11,000
– –
IT icon
161
Gartner
IT
$9.41B
$638K 0.01%
2,100
– –
RDY icon
162
Dr. Reddy's Laboratories
RDY
$9.82B
$554K 0.01%
42,500
– –
SPGI icon
163
S&P Global
SPGI
$126B
$510K 0.01%
1,200
– –
MSCI icon
164
MSCI
MSCI
$40B
$496K 0.01%
816
– –
INTU icon
165
Intuit
INTU
$81.1B
$486K ﹤0.01%
900
– –
MCK icon
166
McKesson
MCK
$98.5B
$484K ﹤0.01%
2,430
– –
DPZ icon
167
Domino's
DPZ
$11B
$477K ﹤0.01%
1,000
– –
MCO icon
168
Moody's
MCO
$81.7B
$444K ﹤0.01%
1,250
– –
AXP icon
169
American Express
AXP
$223B
$436K ﹤0.01%
2,600
– –
LYV icon
170
Live Nation Entertainment
LYV
$41.2B
$428K ﹤0.01%
4,700
– –
A icon
171
Agilent Technologies
A
$39.1B
$425K ﹤0.01%
2,700
– –
TW icon
172
Tradeweb Markets
TW
$21.3B
$420K ﹤0.01%
5,200
– –
FDS icon
173
Factset
FDS
$9.05B
$415K ﹤0.01%
1,050
– –
TRU icon
174
TransUnion
TRU
$14.8B
$415K ﹤0.01%
3,696
– –
EL icon
175
Estee Lauder
EL
$29B
$404K ﹤0.01%
1,348
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.